ArticleNature2017
Promoter-bound METTL3 maintains myeloid leukaemia by m
Open access · greenAbstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 705 papers.
0numbers the graph read from it
0cells of the map it votes in
705citing papers in PubMed
36.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
705 citing papers in PubMed, 1,120 citations in OpenAlex.
- Cell-cycle-driven noncanonical ubiquitination of METTL14 orchestrates RNA methylation.Nature chemical biology · 2026Article
- RNA methylation as a leukemia stem cell vulnerability.Haematologica · 2026Article
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.Trends in cancer · 2026Review
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.Leukemia · 2026Article
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- Structure-aware deep learning enhances m6A prediction and reveals cell type-associated RNA structural signatures.PLoS computational biology · 2026Article
- mNature reviews. Neuroscience · 2026Review
- Review
- Interplay between N6-methyladenosine RNA methylation and protein lactylation: a novel crosstalk linking metabolism and epigenetic regulation in human diseases.Journal of translational medicine · 2026Review
- Article
- A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes prostate cancer proliferation.bioRxiv : the preprint server for biology · 2026Article
- Comprehensive analysis of the RBP regulome reveals functional modules and drug candidates in liver cancer.Scientific reports · 2026Article
- METTL3 regulates exocytosis independently of mScience advances · 2026Article
- mArXiv · 2026Article
- From fragments to full pictures: how long-read sequencing platforms are revolutionizing oncology research.Molecular biology reports · 2026Review
- A novel biclustering algorithm for mining m6A co-methylation patterns based on beta-binomial distribution and data screening strategy.PLoS computational biology · 2026Article
- Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026Review
- RNA modifications and epigenetic regulation in plants.aBIOTECH · 2026Review
645 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Isaia BarbieriThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Konstantinos TzelepisHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
Luca PandolfiniThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Junwei ShiCold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA.
Gonzalo Millán-ZambranoThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Samuel C RobsonThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Demetrios AsprisHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
Valentina MiglioriThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Andrew J BannisterThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Namshik HanThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Etienne De BraekeleerHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
Hannes PonstinglHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
Alan HendrickStorm Therapeutics Ltd, Moneta Building (B280), Babraham Research Campus, Cambridge CB22 3AT, UK.
Christopher R VakocCold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA.
George S VassiliouHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
Tony KouzaridesThe Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
University of Cambridge · GBWellcome Sanger Institute · GBWellcome/Cancer Research UK Gurdon Institute · GBCold Spring Harbor Laboratory · USMission Therapeutics (United Kingdom) · GB
Funding
Cancer Research UK 10827Cancer Research UK 17001Cancer Research UK 23015Cancer Research UK A17001Cancer Research UK A23015European Research Council 268569Medical Research Council MC_PC_12009Wellcome Trust 092096Wellcome Trust 095663Wellcome Trust 098051Wellcome Trust C6946/AI4492Wellcome Trust WT095663MA
Abstract
N
Indexed as
Protein BiosynthesisAdenosineAnimalsCell Line, TumorCell ProliferationChromatinCRISPR-Cas SystemsFemaleGene Expression Regulation, NeoplasticGenes, NeoplasmHumansLeukemia, Myeloid, AcuteMethyltransferasesMicePromoter Regions, GeneticRibosomesAdenosineChromatinMethyltransferasesMETTL3 protein, humanMettl3 protein, mouseN-methyladenosineRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.